Chronic Refractory Cough Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Refractory Cough pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Refractory Cough treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Chronic Refractory Cough Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Refractory Cough Market.

The Chronic Refractory Cough Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Refractory Cough Pipeline Report: https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chronic Refractory Cough treatment therapies with a considerable amount of success over the years.
• Chronic Refractory Cough companies working in the treatment market are Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing therapies for the Chronic Refractory Cough treatment
• Emerging Chronic Refractory Cough therapies in the different phases of clinical trials are- NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others are expected to have a significant impact on the Chronic Refractory Cough market in the coming years.
• In March 2025, Trevi Therapeutics' stock surged over 53% following positive results from its investigational drug Haduvio (nalbuphine hydrochloride), which demonstrated a 57% reduction in cough frequency compared to placebo in patients suffering from chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). In the Phase IIa River trial (NCT05962151)-a double-blind, placebo-controlled study-Haduvio achieved its primary endpoint by significantly reducing 24-hour cough frequency. Notably, clinical benefits were observed even at the lowest dose levels of the oral therapy.
• In December 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company advancing HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has reported positive findings from a human abuse potential (HAP) study evaluating oral nalbuphine.
• In October 2024, Sensory Cloud Inc., a health technology company focused on respiratory treatments, and Hyfe Inc., a leader in AI-driven cough detection, announced encouraging findings from an exploratory clinical study published in ERJ Open Research. The study demonstrated that Sensory Cloud's investigational inhaled alkaline hypertonic divalent salt (HDS) aerosol significantly reduced cough frequency in patients with refractory chronic cough (RCC), with no clinically significant adverse events reported. Cough frequency was continuously monitored using Hyfe Inc.'s AI-powered detection technology. RCC affects an estimated 10% of the global population and has limited treatment options.
• In October 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company advancing HaduvioTM (oral nalbuphine ER) as a potential treatment for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced updates on its ongoing clinical development programs.
• In August 2024, Axalbion, a clinical-stage biopharmaceutical company specializing in innovative treatments for cough, has announced the dosing of the first patient in the second phase of a randomized, placebo-controlled Phase 2 proof-of-concept clinical trial for chronic cough using AX-8, its lead candidate. AX-8 is a highly potent and selective oral agonist targeting the transient receptor potential melastatin 8 (TRPM8) ion channel. To support the trial's progress and Phase 3 preparations, the company has secured additional funding from both existing and new investors.
• In March 2024, Nocion Therapeutics, a clinical-stage biopharmaceutical company, announced securing $62 million in Series B funding. The company is developing innovative small molecule, permanently charged sodium channel blockers (CSCBs), known as nocions, which selectively target activated nociceptors to address conditions like cough, itch, and pain. The funds will support the evaluation of their lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study for Chronic Cough patients.

Chronic Refractory Cough Overview
A cough that lasts longer than eight weeks is referred to as chronic, and many individuals with chronic refractory cough have coughs that last considerably longer. Furthermore, the illness is known as chronic refractory cough when the reason of the persistent cough cannot be found or the cough continues even after receiving the best care possible for any related conditions.

Get a Free Sample PDF Report to know more about Chronic Refractory Cough Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Chronic Refractory Cough Drugs Under Different Phases of Clinical Development Include:
• NOC-100: Nocion Therapeutics
• GDC-6599: Genentech, Inc.
• Haduvio: Trevi Therapeutics
• HRS-2261: Guangdong Hengrui Pharmaceutical Co., Ltd
• BLU-5937: Bellus Health Inc
• MK-7264 (gefapixant): Merck & Co/Kyorin Pharmaceuticals
• Orvepitant Maleate: NeRRe Therapeutics
• Camlipixant (BLU-5937): Bellus Health/GSK
• AX-8: Axalbion
• ADX-629: Aldeyra Therapeutics
• GDC-6599: Genentech, Inc.

Route of Administration
Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical


Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Chronic Refractory Cough Pipeline Therapeutics Assessment
• Chronic Refractory Cough Assessment by Product Type
• Chronic Refractory Cough By Stage and Product Type
• Chronic Refractory Cough Assessment by Route of Administration
• Chronic Refractory Cough By Stage and Route of Administration
• Chronic Refractory Cough Assessment by Molecule Type
• Chronic Refractory Cough by Stage and Molecule Type

DelveInsight's Chronic Refractory Cough Report 4+ covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Refractory Cough product details are provided in the report. Download the Chronic Refractory Cough pipeline report to learn more about the emerging Chronic Refractory Cough therapies
https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Chronic Refractory Cough Therapeutics Market include:
Key companies developing therapies for Chronic Refractory Cough are - Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics and others

Chronic Refractory Cough Pipeline Analysis:
The Chronic Refractory Cough pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.
• Chronic Refractory Cough key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Refractory Cough drugs and therapies
https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Refractory Cough Pipeline Market Drivers
• Increasing Prevalence of cough, growing demand for treatment for Chronic Refractory Cough are some of the important factors that are fueling the Chronic Refractory Cough Market.

Chronic Refractory Cough Pipeline Market Barriers
• However, lack of awareness, lack of availability of specific biomarkers that are useful for accurate and timely diagnosis and other factors are creating obstacles in the Chronic Refractory Cough Market growth.

Scope of Chronic Refractory Cough Pipeline Drug Insight
• Coverage: Global
• Key Chronic Refractory Cough Companies: Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others
• Key Chronic Refractory Cough Therapies: NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others
• Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies
• Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.